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Abstract	
Background	 Traumatic	 brain	 injury	 (TBI)	 is	 associated	 with	 secondary	
complications,	 especially	 infection,	 and	 often	 exhibit	 augmented	 renal	 clearance	
(ARC).	This	phenomenon	has	been	associated	with	subtherapeutic	levels	of	renally	
cleared	 drugs	 such	 as	 vancomycin,	 which	 is	 dosed	 based	 on	 body	 weight	 and	
creatinine	 clearance	 (CrCl).	 Many	 clinicians,	 however,	 cap	 CrCl	 at	 120	
mL/min/1.73m2	 when	 calculating	 vancomycin	 dosing	 regimens.	 We	 hypothesize	
that	capping	patient	CrCl,	as	opposed	to	utilizing	the	actual	CrCl,	when	determining	
vancomycin	dosing	schemes	results	in	subtherapeutic	serum	trough	concentrations,	
and	possibly	therapeutic	failure.	
Methods	This	was	a	retrospective	study	of	adult	patients	with	TBI	admitted	between	
April	 2014	 and	 December	 2015	 who	 received	 vancomycin.	 Population	 based	
pharmacokinetic	 parameters	 using	 actual	 calculated	 CrCl	 and	 capped	 CrCl	 were	
compared	with	patient	specific	pharmacokinetic	parameters	based	on	serum	trough	
concentrations.	
Results	 Thirty-two	 patients	 with	 TBI	 were	 included	 in	 the	 study.	 ARC	 was	
demonstrated	 by	 24	 (75%)	 patients	 with	 a	 median	 CrCl	 at	 serum	 trough	
concentration	of	167.3	(127.7-197.7)	mL/min.	The	mean	dosing	regimen	was	17.1	
(13.2-19.2)	mg/kg	 every	 8	 (8-8)	 h.	 There	was	 no	 difference	 between	 the	median	
measured	 trough	 concentration	 and	 predicted	 value	 using	 actual	 CrCl	 [10.4	 (7.1-
15.0)	 vs.	 11.5	 (7.8-13.7)	 mcg/mL;	 p=0.7986].	 The	 median	 measured	 trough	
concentration	 was	 significantly	 lower	 than	 the	 predicted	 trough	 concentration	
based	on	capping	CrCl	[16.3	(15.3-22.0)	vs.	11.5	(7.8-13.7)	mcg/mL;	p<0.0001].		
Conclusions	 Patients	 with	 traumatic	 brain	 injury	 exhibited	 augmented	 renal	
clearance,	 leading	 to	 subtherapeutic	 vancomycin	 serum	 trough	 concentrations	
when	 doses	 were	 calculated	 using	 the	 traditional	 method	 of	 capping	 creatinine	
clearance	 at	 120	 mL/min/1.73m2.	 Instead,	 utilizing	 patients’	 actual	 creatinine	
clearance	when	 determining	 a	 vancomycin	 dosing	 regimen	 is	more	 accurate,	 and	
provides	a	better	estimation	of	vancomycin	pharmacokinetics	and	could	be	applied	
to	other	renally	excreted	medications.	 	
Introduction	
Traumatic	 brain	 injury	 (TBI)	 is	 often	 associated	 with	 high	 morbidity	 and	
mortality	 rates.1 In	 addition	 to	 the	 physical	 head	 trauma,	 these	 patients	 are	 also	
predisposed	 to	 many	 secondary	 medical	 complications,	 which	 can	 have	 a	 direct	
impact	 on	 patient’s	 overall	 outcome.2,3	 Infection	 is	 one	 of	 the	 most	 common	
secondary	complications	of	TBI,	occurring	in	as	much	as	50%	of	patients	with	TBI.4	
This	 is	 of	 particular	 concern	 because	 infection	 related	 complications	 are	 often	
associated	with	poor	outcomes	including	prolonged	hospitalization	and	an	infection	
related	mortality	rate	as	high	as	28%.5	
Vancomycin	is	an	antibiotic	commonly	prescribed	empirically	in	this	patient	
population	and	is	a	renally	excreted	antibiotic,	traditionally	dosed	based	on	patient	
weight	 and	 creatinine	 clearance	 (CrCl),	 utilizing	 routine	 therapeutic	 drug	
monitoring	to	optimize	its	clinical	efficacy	while	minimizing	toxicity	associated	with	
vancomycin	 exposure.6	 Patients	 with	 TBI,	 however,	 have	 displayed	 an	 increased	
inflammatory	response	and	often	undergo	aggressive	fluid	resuscitation	during	the	
course	of	their	treatment,	possibly	leading	to	the	development	of	augmented	renal	
clearance	 defined	 as	 CrCl	 >130	mL/min/1.73m2.7	 Previous	 studies	 have	 reported	
incidences	 of	 ARC	 in	 patients	 with	 TBI	 greater	 than	 70%.8,9	 This	 enhanced	
glomerular	 filtration	 rate	 puts	 these	 patients	 at	 risk	 for	 therapeutic	 failure	 with	
vancomycin,	which	may	lead	to	poor	outcomes.	In	fact,	a	recent	case	report	suggests	
subtherapeutic	vancomycin	dosing	in	patients	with	TBI,	possibly	due	to	augmented	
renal	 clearance	 (ARC)	 causing	 alterations	 in	 vancomycin	 pharmacokinetic	 (PK)	
parameters,	demonstrating	a	need	for	increased	dosage	of	vancomycin.10	
These	 findings	 raise	 the	 critical	 question	 as	 to	 how	 to	 appropriately	 dose	
vancomycin	with	traumatic	brain	injury.	It	is	common	practice	to	cap	patient	CrCl	at	
120	 mL/min/1.73m2	 when	 calculating	 vancomycin	 doses,	 which	 could	 lead	 to	
therapeutic	failure	due	to	patient’s	increased	renal	function	in	the	setting	to	TBI.	To	
our	knowledge,	no	studies	have	been	conducted	to	evaluate	the	clinical	significance	
of	 capping	 CrCl	 when	 dosing	 vancomycin	 in	 patients	 with	 TBI.	 Therefore,	 the	
purpose	 of	 this	 study	 is	 to	 evaluate	 the	 PK	 parameters	 of	 vancomycin	 in	 the	
presence	 of	 TBI	 and	 determine	 if	 capping	 a	 patient’s	 CrCl	 is	 appropriate	 during	
vancomycin	dosing.	
	
Materials	and	Methods	
Patients	
This	was	 a	 retrospective	 cohort	 study	of	 patients	18	years	 and	older,	 admitted	 to	
UNC	Hospitals	with	traumatic	brain	injury	between	April	1,	2014	and	December	31,	
2015.	This	study	was	approved	by	the	Institutional	Review	Board	with	a	waiver	of	
informed	consent.	Patients	were	included	in	this	study	if	they	received	vancomycin	
and	had	at	least	one	steady	state	vancomycin	serum	trough	concentration	recorded	
in	 their	 electronic	 medical	 record	 (EMR).	 Patients	 were	 excluded	 if	 they	 were	
pregnant,	had	renal	dysfunction	(chronic	kidney	disease	stages	3-5	and/or	a	serum	
creatinine	 >1.4	 mg/dL),	 received	 a	 renal	 replacement	 during	 admission,	 had	 a	
history	of	nephrectomy,	or	had	a	body	mass	index	<18	kg/m2.	Patient data collected 
include: age, gender, height, weight, renal function (creatinine clearance [CrCl] and 
serum creatinine [SCr]), Glasgow Coma Scale (GCS) score, Sequential Organ Failure 
Assessment (SOFA) score, comorbidities (hypertension, diabetes mellitus, atrial 
fibrillation, and congestive heart failure), concomitant antibiotic use, fluid balance, 
infection type, ICU length of stay (LOS), and hospital LOS. Factors that might have 
affected vancomycin clearance were evaluated as well, including treatment with 
temperature modulation, vasopressors, and diuretics. Vancomycin-specific data collected 
include: vancomycin dose and frequency, duration of vancomycin therapy, time from 
admission to first vancomycin dose, and time between a trough-associated dose and the 
previous dose.  
	
Vancomycin	Dosing	Regimens	
Clinical	 pharmacists	 are	 consulted	 for	 vancomycin	 initiation	 for	 patients	
admitted	to	the	Neurosciences	Intensive	Care	Unit	at	UNC	Hospitals.	The	consulted	
clinical	 pharmacist	 is	 also	 responsible	 for	 determining	 the	 vancomycin	 dosing	
regimens	and	optimal	time	to	obtain	a	serum	trough	concentration,	typically	at	least	
four	times	the	half-life	of	the	drug	after	administration.	The	goal	serum	vancomycin	
trough	concentration	at	steady	state	is	15-20	mcg/mL,	depending	on	the	indication.	
	
Pharmacokinetic	Measures	
The	primary	outcome	was the difference in actual vancomycin pharmacokinetic 
parameters determined by serum trough concentrations compared with population 
predicted values in patients with TBI when capping CrCl versus using actual calculated 
CrCl. Specifically, half-life (t1/2), elimination rate constant (ke), and volume of 
distribution (Vd) were evaluated. Predicted pharmacokinetic parameters were calculated 
using standard population pharmacokinetic equations:11  
 
ke (predicted) = 0.00083 * CrCl + 0.00443 
Vd (predicted) = 0.7 L/kg actual body weight [actBW]	
 
CrCl is the estimated creatinine clearance based on the Cockcroft-Gault equation,12 using 
measured (not rounded) SCr values. The weight used in the Cockcroft-Gault equation 
was determined as follows:13,14 
 
1) If actBW ≤ ideal body weight (IBW) → use actBW 
2) If IBW < actBW ≤ 125% of IBW → use IBW 
3) If actBW > 125% of IBW → use adjusted body weight (adjBW) 
 
IBW = (50 kg if male | 45 kg if female) + 2.3(height in inches – 60) 
AdjBW = IBW + 0.4(actBW – IBW) 
 
The estimated serum vancomycin serum trough concentration was calculated using 
predicted pharmacokinetic parameters and compared to the actual, patient specific 
measured serum vancomycin trough concentration. The following equation was used to 
calculate patient pharmacokinetic parameters based on measured steady-state serum 
vancomycin trough concentrations:15 
 
ke (actual) = ln[(dose/Vd + Cmin) / Cmin] / τ, 
 
where Vd is the volume of distribution, ke is the elimination rate constant, Cmin is the 
steady-state serum vancomycin trough concentration, and τ is the dosing interval. This 
equation operates under assumptions of steady-state bolus dosing in a one-compartment 
model, to improve feasibility of calculations. 
	
Statistical	Analysis	
Baseline patient characteristics and vancomycin regimen characteristics were 
described using descriptive statistics. Categorical variables are represented as n (%) while 
continuous and ordinal variables are represented as median (interquartile range, IQR). 
Predicted pharmacokinetic parameters based on population data were compared to the 
actual, patient specific pharmacokinetic parameters obtained from collected steady-state 
vancomycin serum trough concentrations using the Wilcoxon signed-rank test (or paired 
t-test when the paired differences were normally distributed, as determined by Shapiro-
Wilk testing). A p value < 0.05 was considered statistically significant. All statistical 
analyses were carried out with Stata SE version 15.0 (StataCorp LP, College Station, 
TX). 
	
Results	
	 There	 were	 34	 adult	 patients	 with	 TBI	 who	 received	 vancomycin	 with	 at	
least	 one	 steady	 state	 serum	 trough	 concentration	 during	 the	 study	 period.	 Two	
patients	were	excluded	due	to	renal	dysfunction,	thus	analysis	was	conducted	on	32	
total	patients.		
	
Baseline	Patient	Characteristics		
	 Baseline	characteristics	for	all	patients	included	in	the	study	are	described	in	
Table	1.	Patients	were	primarily	male	(72%)	with	a	median	age	of	36	years	(24.5-
52).	The	median	GCS	was	7	(5-10)	and	median	SOFA	score	was	5	(3-7).	The	median	
baseline	 creatinine	 clearance	 (CrCl)	 of	 patients	 was	 116	 (96-130.5)	 mL/min,	
calculated	using	the	Cockroft	and	Gault	equation.	
	
Vancomycin	Characteristics		
Table	 2	 displays	 patient	 vancomycin	 characteristics.	 The	 mean	 number	 of	
days	 from	 injury	 to	 vancomycin	 serum	 trough	 concentration	 was	 7.2	 ±	 4.7.	 The	
median	 vancomycin	 dosing	 regimen	 was	 17.1	 (13.2-19.2)	 mg/kg	 every	 8	 (8-8)	
hours.	Pneumonia	and	empiric	coverage	were	the	two	most	common	indications	for	
prescribing	 vancomycin	 as	 pneumonia	 accounted	 for	 53.1%	 of	 infections	 (n=17)	
and	 43.8%	 of	 patients	 were	 dosed	 empirically	 (n=14).	 The	 median	 estimated	
vancomycin	 volume	 of	 distribution	 was	 54.8	 (48.8-63.98)	 L.	 Patients	 were	
aggressively	 fluid	 resuscitated	with	 a	 net	 positive	mean	 fluid	 balance	 of	 2064.5	 +	
1957.8	mL/day,	 and	 had	 an	 elevated	median	 creatinine	 clearance	 at	 the	 time	 the	
vancomycin	 trough	 concentration	 was	 drawn	 [167.3	 (127.7-197.7)	 mL/min]	
compared	to	their	baseline	creatinine	clearance	upon	admission.		
	
Vancomycin	Pharmacokinetic	Parameters		
	 The	 predicted	 population	 based	 pharmacokinetic	 parameters	 using	 both	
capped	 CrCl	 as	 well	 as	 actual	 CrCl	 and	 the	 patient	 specific	 pharmacokinetic	
parameters	 based	 on	 steady	 state	 vancomycin	 serum	 trough	 concentrations	 are	
displayed	 in	 Table	 3.	 Using	 actual	 CrCl,	 there	was	 no	 difference	 between	median	
predicted	and	patient	specific	elimination	rate	constants	 [0.14	(0.11-0.17)	vs.	0.13	
(0.12-0.15)	 hr-1;	 p=0.7371].	 The	 median	 predicted	 and	 measured	 serum	 trough	
concentrations	using	actual	CrCl	were	also	not	statistically	different	[10.4	(7.1-15.0)	
vs.	11.5	(7.8-13.7)	mcg/mL;	p=0.7986].	In	contrast,	both	predicted	elimination	rate	
constant	and	predicted	serum	trough	concentration	using	the	traditional	method	of	
capping	 CrCl	 were	 significantly	 different	 compared	 to	 the	 median	 calculated	
elimination	rate	constant	and	patient	specific	measured	serum	trough	concentration	
[0.104	 (0.104-0.104)	 vs.	 0.13	 (0.12-0.15);	 p<0.0001,	 and	 16.3	 (15.3-22.0)	 vs.	 11.5	
(7.8-13.7)	mcg/mL;	p<0.0001,	respectively].	
	
Discussion	
	 Limited	 evidence	 has	 been	 published	 to	 evaluate	 vancomycin	
pharmacokinetic	 dosing	 strategies	 in	 patients	with	 traumatic	 brain	 injury.	 In	 this	
study,	 patients	 with	 TBI	 exhibited	 pharmacokinetic	 alterations	 consistent	 with	
increased	 vancomycin	 clearance.	 From	 admission	 to	 the	 time	 the	 serum	 trough	
concentration	was	drawn	(~7	days)	patients’	CrCl	increased	by	an	average	of	44%.	
The	 vast	majority	 of	 patients	 in	 this	 study	had	 indications	 for	 vancomycin	 trough	
concentrations	 of	 15-20	 mcg/mL,	 however,	 the	 noted	 increase	 in	 renal	 function	
correlated	with	 subtherapeutic	 trough	 concentrations	 even	with	 high	 vancomycin	
doses	of	approximately	17	mg/kg	every	8	hours.	
Most	 patients	 in	 this	 study	 had	 CrCl	well	 above	 120	mL/min	with	 75%	 of	
patients	 displaying	 ARC	 (CrCl	 >130	 mL/min/1.73m2)	 with	 a	 median	 CrCl	 of	 167	
mL/min.	Our	study	showed	similar	 incidences	of	ARC	 in	our	patient	population	as	
previously	published	studies.	A	recent	study	by	Carrie	and	colleagues	reported	73%	
of	patients	with	severe	TBI	exhibiting	ARC,9	while	a	 study	by	Udy,	et	al.	 exploring	
changes	 in	 renal	 function	 in	 patients	with	TBI	 reported	 an	of	ARC	 incidence	 of	 at	
least	 75%.8	 The	 results	 of	 this	 study	 contrast	 a	 published	 study	 by	 Oswalt	 and	
colleagues,	 however,	 which	 found	 patients	 with	 TBI	 to	 have	 a	 larger	 mean	
population	predicted	elimination	rate	constant	than	the	patient	specific	elimination	
rate	constant	by	0.031	h-1	(95%	CI:	-0.04	to	-0.022),	indicating	a	less	rapid	clearance	
of	 vancomycin	 than	 predicted	 by	 population	 PK.16	 Our	 study	 and	 a	 study	 by	
Morbitzer	 et	 al.,	 however,	 demonstrated	 patients	 with	 TBI	 cleared	 vancomycin	
much	more	 rapidly	 than	predicted	by	population	PK.6	Both	 the	 current	 study	and	
that	conducted	by	Oswalt	and	colleagues,	however,	report	at	 least	75%	of	patients	
experiencing	subtherapeutic	vancomycin	concentrations.16	While	we	agree	with	the	
conclusions	drawn	by	Oswalt	and	colleagues	supporting	the	use	of	population	PK	to	
estimate	 empiric	 vancomycin	 dosing	 regimens,	 this	 method	 must	 be	 modified	 to	
ensure	 appropriate	 vancomycin	 targets	 are	 achieved	 given	 the	 high	 incidence	 of	
ARC,	consequently	resulting	in	subtherapeutic	levels	of	vancomycin	with	traditional	
dosing	calculations.		
In	 healthy	 individuals,	 normal	 renal	 function	 is	 between	 120-130	
mL/min/1.73m2	 depending	 on	 gender,	 race	 and	 body	 surface	 area.17	 While	
vancomycin	 dosing	 is	 often	 modified	 based	 on	 renal	 impairment,	 very	 little	
attention	 has	 been	 given	 to	 the	 opposite	 end	 of	 the	 spectrum	 and	 how	 to	 adjust	
medication	 doses	 in	 the	 setting	 of	 enhanced	 renal	 function.	 In	 fact,	 when	 dosing	
vancomycin,	 pharmacists	 and	 many	 online	 calculators	 often	 cap	 patients’	 CrCl	 at	
120	mL/min.18	Using	this	capped	CrCl	 in	calculating	a	vancomycin	dosing	regimen	
would	 typically	 result	 in	a	 therapeutic	vancomycin	 serum	 trough	concentration	 in	
patients	 with	 normal	 renal	 function,	 however,	 our	 results	 showed	 that	 when	
applying	this	same	practice	to	patients	with	TBI	resulted	in	a	median	serum	trough	
concentration	of	11.5	(7.8-13.7)	mcg/mL,	indicating	subtherapeutic	concentrations.	
Conversely,	 when	 using	 patients	 actual	 CrCl	 to	 determine	 an	 appropriate	
vancomycin	dosing	regimen,	therapeutic	levels	are	more	likely	to	be	attained	[16.3	
(15.3-22.0)	vs	11.5	(7.8-13.7)	mcg/mL;	p	<0.0001]. 
This	 study	 had	 several	 limitations.	 First,	 population	 predicted	
pharmacokinetic	 parameters	 were	 calculated	 using	 a	 one-compartment	 model,	
under	 assumptions	 of	 steady-state	 bolus	 dosing	 (instead	 of	 infusion	 dosing)	 to	
facilitate	more	 tractable	 calculations.	However,	 in	 situations	of	 faster	 clearance	or	
increased	 infusion	 duration,	 these	 equations	 start	 to	 deviate	 from	 steady-state	
infusion	 dosing	 equations.	 Volumes	 of	 distribution	 were	 computed	 using	 the	
population	estimation	equation	of	0.7	L/kg.	Vancomycin	 levels	 (either	a	peak	or	a	
random	level	on	the	same	dosing	curve)	would	have	had	to	be	collected	to	calculate	
actual	 volumes	 of	 distribution,	 which	 were	 not	 available	 given	 the	 retrospective	
nature	 of	 the	 study.	 The	 Cockcroft-Gault	 equation	 used	 to	 estimate	 CrCl	 was	
originally	designed	for	use	in	a	more	ambulatory	setting	rather	than	in	the	critically	
ill,	so	the	estimate	 it	provides	 in	this	population	may	not	be	as	precise	as	using	8-
hour	urine	collection.7	Finally,	information	on	clinical,	microbiological,	or	functional	
outcomes	 after	 the	 initial	 study	 period	 was	 not	 collected.	 The	 small	 sample	 size	
limits	external	validity,	as	well.	
There	 are	 several	 avenues	 for	 further	 investigation.	 A	 larger,	 prospectively	
designed	study	in	which	vancomycin	peak	and	trough	concentrations	are	drawn	at	
steady-state	 would	 allow	 for	 more	 accurate	 calculation	 of	 actual,	 patient	 specific	
pharmacokinetic	 parameters.	 Similarly,	 using	measured	 creatinine	 clearances	 (e.g.	
using	 an	8-hour	 urine	 collection	method,	 extrapolated	 to	 24	hours)	would	permit	
more	 accurate	 assessments	 of	 renal	 function,	 and	 may	 even	 be	 able	 to	 discern	
augmented	 renal	 clearance.	 The	 use	 of	 first-dose	 kinetics	 vs.	measured	 creatinine	
clearances	(in	conjunction	with	population	pharmacokinetic	equations)	early	in	the	
treatment	course	can	be	compared	in	their	respective	rates	of	achieving	therapeutic	
trough	 levels,	and/or	AUC:MIC	 targets.	 Incorporation	of	other	outcomes,	 including	
clinical	 cure,	microbiological	 cure,	and	 longer-term	 functional	outcomes,	would	be	
instructive	as	well	to	evaluate	the	clinical	significance	of	this	dosing	strategy.		
	
Conclusions	
This	study	evaluated	the	 impact	of	 the	common	practice	of	capping	CrCl	on	
vancomycin	 dosing	 in	 patients	 with	 traumatic	 brain	 injury.	 When	 vancomycin	
dosing	 regimens	 were	 calculated	 using	 a	 capped	 CrCl	 of	 120	 mL/min,	 patients	
experienced	 subtherapeutic	 serum	 trough	 concentrations.	 This	 resulted	 in	
underexposure	 to	 vancomycin,	 potentially	 leading	 to	 treatment	 failure.	
Alternatively,	 using	 patient’s	 actual	 CrCl	 to	 calculate	 an	 appropriate	 dose	 of	
vancomycin	 correlated	 very	 well	 to	 measured	 serum	 trough	 concentrations.	 This	
data	 implies	 that	 actual	 CrCl	 is	 more	 accurate	 at	 predicting	 vancomycin	
pharmacokinetics	 and	 should	 be	 utilized	 in	 dosing	 calculations	 over	 the	 common	
practice	 of	 capping	 CrCl.	 These	 findings	 also	 highlight	 the	 importance	 of	 close	
therapeutic	monitoring	of	renally	excreted	medications	in	patients	with	TBI.	
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Table	1-	Baseline	Patient	Characteristics		
Variable	 Patients	(n=32)	
Age	(yrs),	median	(IQR)	 36	(24.5-52)	
Weight	(kg),	mean	±	SD	 80.8	±	20	
Male	sex-	no.	(%)	 23	(72)	
Admission	GCS,	median	(IQR)	 7	(5-10)	
Admission	SOFA,	median	(IQR)	 5	(3-7)	
TBI	Type,	n	(%)	
					Blunt	
					Penetrating	
	
27	(84)	
5	(16)	
Non-TBI	Trauma,	n	(%)	
					Chest	
					Abdominal	
					Extremity	
					Spinal	
16	(50)	
					6	(18.75)	
					4	(12.5)	
					6	(18.75)	
					6	(18.75)	
Admission	SCr	(mg/dL),	mean	±	SD	 0.86	±	0.26	
Admission	CrCl	(mL/min),	median	(IQR)	 116	(96-130.5)	
Selected	Co-Morbidities	
					Hypertension	
					Diabetes	
					Congestive	Heart	Failure	
	
7	(21.9)	
2	(6.75)	
1	(3.12)	
GCS,	Glasgow	Coma	Scale;	SOFA,	Sequential	Organ	Failure	Assessment;	SCr,	Serum	
Creatinine;	CrCl,	Creatinine	Clearance	calculated	from	Cockroft	and	Gault	Equation	
Table	2-	Vancomycin	Characteristics	
Variable	 Patients	(n=32)	
Days	from	Injury	to	Serum	Concentration,	mean	±	SD	 7.2	±	4.7	
Dose	(mg/kg),	median	(IQR)	 17.1	(13.2-19.2)	
Frequency	(hours),	median	(IQR)	 8	(8-8)	
CrCl	at	trough	level	(mL/min),	median	(IQR)	 167	(128-198)	
Estimated	Volume	of	Distribution	(L),	median	(IQR)	 54.81	(48.8-63.98)	
Daily	Fluid	Balance	of	48	Hours	Prior	to	Serum	
Concentration	(mL/day),	mean	±	SD	
+2064.5	±	1957.8	
Source	of	Infection,	n	(%)	
					Empiric	
					Respiratory	
					Other	
	
14	(43.75)	
17	(53.12)	
1	(3.12)	
	
	 	
Table	3-	Vancomycin	Pharmacokinetic	Parameters	
	 Elimination	Rate	
Constant	(hr-1),	
median	(IQR)	
p	–	value	 Serum	Trough	
Concentration	
(mcg/mL),	
median	(IQR)	
p	–	value	
Measured,	
Patient	
Specific	Value	
0.13	(0.12-0.15)	 	 11.5	(7.8-13.7)	 	
Population	
Predicted	
Value,	Actual	
CrCl	
0.14	(0.11-0.17)	 0.7371	 10.4	(7.1-15.0)	 0.7986	
Population	
Predicted	
Value,	Capped	
CrCl	
0.104	(0.104-0.104)	 <0.0001	 16.3	(15.3-22.0)	 <0.0001	
	
	
